Ann: Phosphagenics Initiates Arbitration Against Mylan, page-3

Answers or questions stormer?

Meanwhile the licensing agreement continues in full force and effect......

I'm reading that we have Mylan by the short and curlies here.

Daptomycin it is, and there's the specific mention of generic competition by June 2016.

So the question is does the new composition possible extend the patent on Daptomycin?

One feels how quickly this is resolved comes down to how badly Mylan need this and my guess is this will never go to arbitration, as it will need to be resolved by June 2016, and if so we will have our second pharmaceutical product with TPM, but this time global, and not just India and one would feel on much better terms.

I think POH must have been bursting at the seems to get his public.

The patent itself is probably the best validation we've had of a TPM capability, although not quite the mechanism we had all envisaged from the start.